Related Experiment Video
Updated: Jul 24, 2025

Acute Myocardial Infarction in Rats
Published on: February 16, 2011
A Rare Case of Regorafenib-Induced ST-Elevation Myocardial Infarction
Sadichhya Karki1, Vaishali Deenadayalan1, Prajwal Shrestha1
1Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA.
Abstract:
Regorafenib is an oral multi-kinase inhibitor that is used in the treatment of chemotherapy-resistant metastatic colorectal carcinoma. However, multi-kinase inhibitors have been known to cause cardiac side effects, most notably hypertension. Myocardial ischemia is a very extraordinary adverse effect of regorafenib. Our patient was a 74-year-old gentleman with stage IVa colon cancer who underwent a right colectomy with end ileostomy and was on cycle two of regorafenib during the presentation. He came in with acute onset chest pain that was intermittent, non-exertional, and radiating to the back. His left heart catheterization did not reveal any atherosclerotic lesions, and his ST-elevation myocardial infarction (STEMI) was deemed an extremely rare adverse event from regorafenib. We are herewith reporting a case of regorafenib-induced STEMI.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Myocarditis III: Medical Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

